Last reviewed · How we verify
BoNT Injections
At a glance
| Generic name | BoNT Injections |
|---|---|
| Sponsor | National Institute of Neurological Disorders and Stroke (NINDS) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Viral upper respiratory tract infection
- COVID-19
- Injection site bruising
- Injecttion Site Pain
- Upper respiratory tract infection
- Sinusitis
- Influenza
- Urinary tract infection
- Nasopharyngitis
- Corona virus infection
- Muscle strain
Key clinical trials
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
- Dual-Site Botulinum Toxin Type A Injection for Lifelong Premature Ejaculation (NA)
- Phenol and Botulinum Toxin vs Botulinum Toxin Alone for Post-Stroke Upper-Limb Spasticity (PHASE4)
- Overlooked Barrier To Discontinuing Bont-A Therapy
- UltraSound-Guided Versus Non-Ultrasound-Guided Botulinum Toxin Injections in Cervical Dystonia [CUSTODY] (NA)
- Exoskeleton Robotic Assisted Gait Training in Spastic Stroke Post Botulinum Toxin A Injection (NA)
- Repeated Botulinum Toxin Type A Injections on Intramuscular Fat Accumulation in Individuals With Sleep Bruxism. (NA)
- Comparing Upper Limb Surgery and Botulinum Toxin for Spasticity: A Paired Design Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BoNT Injections CI brief — competitive landscape report
- BoNT Injections updates RSS · CI watch RSS
- National Institute of Neurological Disorders and Stroke (NINDS) portfolio CI